Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsThe pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.
Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.
Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO
1.
Obesity linked to subsequent neoplasms in childhood cancer survivors
2.
Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.
3.
For the first time in humans, a chemotherapy drug reaches the brain.
4.
Study: For predicting breast cancer, AI performs better than traditional risk models.
5.
Resection for Early Liver Cancer Tied to Improved Survival.
1.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
2.
Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options
3.
AI in Genomics: Decoding the Human Genome for Cancer Treatment
4.
Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership
5.
How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
4.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
5.
Navigating the Complexities of Ph Negative ALL - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge